Long-Range Coupling in an Allosteric Receptor Revealed by Mutant Cycle Analysis  by Gleitsman, Kristin R. et al.
Long-Range Coupling in an Allosteric Receptor Revealed by Mutant
Cycle Analysis
Kristin R. Gleitsman,† Jai A. P. Shanata,† Shawnalea J. Frazier,‡ Henry A. Lester,‡ and Dennis A. Dougherty†*
†Divisions of Chemistry and Chemical Engineering and ‡Biology, California Institute of Technology, Pasadena, California 91125
ABSTRACT The functional coupling of residues that are far apart in space is the quintessential property of allosteric proteins.
For example, in Cys-loop receptors, the gating of an intrinsic ion channel is allosterically regulated by the binding of small mole-
cule neurotransmitters 50–60 A˚ from the channel gate. Some residues near the binding site must have as their primary function
the communication of the binding event to the gating region. These gating pathway residues are essential to function, but their
identiﬁcation and characterization can be challenging. This work introduces a simple strategy, derived from mutant cycle anal-
ysis, for identifying gating pathway residues using macroscopic measurements alone. In the exemplar Cys-loop receptor, the
nicotinic acetylcholine receptor, a well-characterized reporter mutation (bL90S) known to impact gating, was combined with muta-
tions of target residues in the ligand-binding domain hypothesized or previously found to be functionally signiﬁcant. A mutant
cycle analysis of the macroscopic EC50 measurements can then provide insights into the role of the target residue. This new
method, elucidating long-range functional coupling in allosteric receptors, can be applied to several reporter mutations in
a wide variety of receptors to identify previously characterized and novel mutations that impact the gating pathway. We support
our interpretation of macroscopic data with single-channel studies. Elucidating long-range functional coupling in allosteric recep-
tors should be broadly applicable to determining functional roles of residues in allosteric receptors.
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Cys-loop receptors mediate fast synaptic transmission
throughout the central and peripheral nervous systems
(1–4). These pentameric, ligand-gated ion channels are proto-
typical allosteric receptors (5), in that the activation (gating) of
an intrinsic ion channel is allosterically regulated by the
binding of small molecule neurotransmitters (acetylcholine
(ACh), serotonin, GABA, or glycine). Although valuable
structural insights for Cys-loop receptors have appeared in
recent years (6,7), detailed conformational mechanisms
linking neurotransmitter binding to channel gating remain
elusive.
Structurally, Cys-loop receptors have two principal func-
tional domains (Fig. 1). The extracellular domain, rich in
b-sheet structure, contains the agonist binding sites. Each
subunit also contains a transmembrane domain comprised
of four membrane-spanning helices, one of which (M2) lines
the ion channel. Although the precise location of the channel
gate has been debated, the consensus positions it at or below
the middle of the M2 helix. This puts the channel gate
50–60 A˚ away from the agonist binding sites. Neurotrans-
mitter binding events must therefore be communicated
over this distance to the channel gate.
In terms of function, such a clear demarcation of domains
is less evident. For a given residue, if a mutation at the site
leads to a change in receptor function, this could be because
the binding of agonist or the gating of the channel (or both)
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0006-3495/09/04/3168/11 $2.00has changed. It seems safe to say that residues in the middle
of the transmembrane domain do not contribute directly to
agonist binding, and so residues in the transmembrane
domain that contribute to function are typically described
as ‘‘gating’’ residues. In contrast, one expects to find resi-
dues in the extracellular domain with varying functional
roles. Some residues will primarily facilitate agonist
binding, either by directly contacting the agonist or by
refining the shape or electronic properties of the agonist
binding site. However, to achieve the long-range communi-
cation that is fundamental to Cys-loop receptor function,
other extracellular domain residues must be involved in
communicating the binding event to the channel gate,
serving an instrumental role in the gating pathway. These
gating pathway residues are in some ways the most inter-
esting, but their identification and characterization can be
challenging.
One strategy for determining whether a given residue
primarily contributes to agonist binding or channel gating
involves single-channel recording on appropriate mutants,
followed by kinetic analysis. However, in some Cys-loop
receptors (such as 5-HT3 (8)), single-channel conductances
are too small for reliable kinetic analyses (9,10); in many
other Cys-loop receptors, single-channel kinetics are
complex or nonstationary, again vitiating single-channel
kinetic analysis (11,12). Also, in other ion channels (13)
and in allosteric receptors in general, single-channel studies
are often not possible.
A more broadly applicable approach, allowing one to effi-
ciently evaluate a number of mutants in search of unusual
behavior, is to measure macroscopic currents across multiple
concentrations. This produces the EC50 value, the
doi: 10.1016/j.bpj.2008.12.3949
concentration that induces half-maximal current in response
to applied agonist, along with comparative measurements of
maximal agonist-induced currents. In the case of ligand-gated
ion channels, EC50 is a composite value, being responsive to
both changes in agonist binding and channel gating behaviors.
As such, it can be challenging to interpret shifts in EC50. Here
we describe an approach to use the readily obtained EC50
values to identify residues that substantially impact receptor
gating. We refer to the method as ELFCAR (elucidating
long-range functional coupling of allosteric receptors). The
basic tool involves mutant cycle analysis of EC50 values for
distant pairs of mutation sites. Complementary observations
FIGURE 1 Residues considered here. Shown are two adjacent subunits of
the cryo-EM structure of the Torpedo nAChR (pdb 2BG9) (7). The reporter
residues in the transmembrane domain are shown as cyan and are labeled.
Residues in the extracellular domain are in two classes: those with no
long-range coupling (purple), and the five residues that show significant
long-range coupling (orange). One noncoupling residue (gE168) is not
defined in the EM structure and so is not shown.
Long-Range Coupling in Receptorsconcerning mutational effects on receptor efficacy and the
effects of partial agonists (PAs) support the basic method-
ology. Thus, ELFCAR provides an efficient strategy for iden-
tification of key gating pathway residues that may otherwise
evade detection, without performing single-channel studies.
Key to the approach is the definitive feature of allosteric
proteins: action at a distance. When a mutation in the trans-
membrane domain that is unambiguously associated with
channel gating is paired with various mutations in the extra-
cellular domain, the observation of nonmultiplicative EC50
shifts for the two mutations signals a functional coupling
between the two residues, and thus identifies the extracellular
domain mutation as influencing gating. We show that this
behavior derives from the typical allosteric kinetic scheme
for Cys-loop receptors, suggesting the approach could
provide a general probe of allosteric receptors.
METHODS
Site-directed mutagenesis
Fetal mouse muscle nicotinic ACh receptor (nAChR) a-, b-, g-, d-subunits
were utilized in the experiments. Each subunit was expressed in pAMV
vectors. Mutations were made at the site of interest using a standard Strata-
gene QuikChange protocol. For the incorporation of unnatural residues, the
site of interest was mutated to the amber stop codon. In addition, the
a-subunits contain an HA epitope in the M3-M4 cytoplasmic loop for
Western blot studies. Control experiments show that this epitope does not
detectably alter EC50. Primers were designed to fulfill the established criteria
and were ordered from integral DNA technologies. Polymerase chain
reaction (PCR) reactions were carried out using a high-fidelity Pfu DNA
polymerase, and a 10 min extension time was used in each thermocycle. An-
nealing temperatures were modified as required for successful incorporation
of the mutation. DpN1 digestion was used to eliminate methylated template
DNA from the PCR products. After PCR purification (Qiagen standard
protocol), amplification of the PCR product was conducted by electropora-
tion with Super Competent Top 10 Escherichia coli followed by 12 h of
growth on agar/Luria broth/ampicillin plates. Single colonies were selected
and amplified in liquid Luria broth/ampicillin culture. The DNA was isolated
from the bacteria (Qiagen, miniprep kit) and sequenced to verify the success-
ful incorporation of the mutation at the selected site.
The circular bacterial plasmid of the mutation-containing DNA was line-
arized using a Not1 restriction enzyme. Linearized plasmids were used as the
DNA template for in vitro transcription using T7 mMessage mMachine
enzyme kits (Ambion) to make mRNA. Quantification of mRNA was deter-
mined using a NanoDrop spectrophotometer (NanoDrop Technologies,
Thermo Scientific, Wilmington, DE).
For conventional mutations, the stoichiometry of subunits was 2:1:1:1 of
a/b/g/d by mass with a total mRNA concentration of ~2 mg/mL. For unnat-
ural mutations (14), a total of 40 ng of mRNA in a 10:1:1:1 a/b/g/d-subunit
was coinjected with the synthetic a-hydroxy acids conjugated to the dinucle-
otide dCA and ligated to truncated 74-nucleotide tRNA as previously
described. mRNA/tRNA were typically 1:1.
Stage V–VI oocytes of Xenopus laevis (Nasco, Fort Atkinson, WI) were
injected with 50 nL of the mRNA or mRNA/tRNA mixture. The oocytes
were incubated in culture media containing 1–2% horse serum at 18C.
Whole-cell electrophysiology
Whole-cell electrophysiological recordings were performed on injected
Xenopus laevis oocytes after 12–36 h incubation. Recording was done in
two-electrode voltage clamp mode using the OpusXpress 6000A (Axon
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solution (in mM: 96 NaCl, 2 KCl, 1 MgCl2, 5 HEPES) at flow rates of 4 mL/
min during drug application (15 s) and 3 mL/min during wash (130 s).
Macroscopic agonist-induced currents were recorded in response to bath appli-
cation of the indicated agonist concentrations at 60 mV or 80 mV. Data
were sampled at 125 Hz and filtered at 50 Hz. ACh chloride and succinylcho-
line (SuCh) chloride were purchased from Sigma/Aldrich/RBI (St. Louis,
MO). Agonist solutions ranging from 0.0100 mM to 5000 mM were prepared
in Ca2þ-free ND96 from a 1 M stock solution. Dose-response relations were
constructed for each mutation using data from R5 oocytes. Dose-response
relations were fitted to the Hill equation (Eq. 1) to determine the EC50 and
the Hill coefficient:
I=Imax ¼ 1=ð1 þ ðEC50=½AÞnHÞ; (1)
where I is the current for agonist concentration [A], Imax is the maximum
current, EC50 is the concentration to elicit half maximal response, and nH
is the Hill coefficient. The dose-response relations of individual oocytes
were examined and used to determine outliers. The reported EC50 values
are from the curve fit of the averaged data.
Single-channel characterization of selected gating
pathway residue mutants
Single-channel recording was performed in the cell-attached configuration
on devitellinized oocytes 24–60 h after injection at 20  3C with an applied
pipette potential of þ100 mV, as described previously (15). Pipettes were
fabricated from thick-walled (inner diameter ¼ 0.80 mm, outer diameter ¼
1.60 mm) KG-33 glass (Garner Glass, Claremont, CA) and coated with
Sylgard (World Precision Instruments, Sarasota, FL); they had resistances
of 8–25 MU. The bath solution contained, in mM, 120 KCl, 5 HEPES,
1 MgCl2, 2 CaCl2, pH ¼ 7.4, so that the transmembrane potential of the
patch was 100 mV, and the reversal potential for agonist-induced currents
was ~0 mV. The pipette solution contained, in mM, 100 KCl, 10 HEPES,
1 MgCl2, 10 K2EGTA, pH ¼ 7.4 and was supplemented with the indicated
concentrations of ACh using a 1 M stock solution.
Before single-channel recording, whole-cell expression levels were deter-
mined with 100–1000 mM ACh doses using the whole-cell recording condi-
tions on each mutant. When whole-cell expression exceeded ~300 nA for
receptors with the target mutation alone and ~3 mA for receptors with a target
mutation and a reporter mutation, oocytes were typically incubated 4–10
additional h before single-channel recording. Data were collected using
a GeneClamp 500B amplifier (Axon Instruments, Union City, CA) with
a CV-5 100 GU headstage at full bandwidth (4-pole Bessel, 3 dB, 50 kHz).
The signal was then low-pass filtered (8-pole Bessel, 3 dB, 20 kHz) and
sampled with a Digidata 1320A and Clampex 9.2 (Axon Instruments, Union
City, CA) at 50 or 100 kHz. Only recordings that showed no simultaneous
activations were included in NPopen analysis. In this manner,Rthree patches
at EC50 were analyzed for all mutants, except for the abgD174NdD180N
and abL90S gD174NdD180N mutants for which two patches each were ob-
tained. Data were filtered offline (Gaussian, 3 dB, 5 kHz) and electrical
interference at harmonics of 60 Hz was removed, if necessary. Event transi-
tions were detected with Clampfit 9.2 (single-channel search). A dead time,
td, of 40 ms was applied to all events. The time-average probability that
exactly one channel in the patch is open (NPopen) was calculated as the
total open time divided by the sum of the total open time and the total
closed time.
RESULTS
The prototypical and most-studied Cys-loop receptor, the
muscle nicotinic ACh receptor (nAChR), was used in this
study. It is important to appreciate that the method is directly
applicable to other Cys-loop receptors, and, in favorable
Biophysical Journal 96(8) 3168–3178cases, to other allosteric proteins as well. Here we have em-
ployed the muscle-type nAChR as a well-established system
that allows us to evaluate the methodology.
The muscle nAChR is a heteropentamer with subunit
composition (a1)2b1gd. Two nonequivalent binding sites
are located in the extracellular domain at the ad and
ag-subunit interfaces. Nearly all Cys-loop receptors,
including all nAChRs, contain a conserved leucine residue
in the hydrophobic, pore-lining M2 helix of each subunit
(Fig. 1). Mutating this residue, termed L90, to serine lowers
the EC50 (16,17). Structural studies place L9
0 near the middle
of the M2 helix, in the region of the occlusion of the closed
channel, and although it can be debated whether L90 consti-
tutes a literal gate of the channel, there can be no doubt that it
is a crucial gating residue. In this work, the L90S mutation in
the b-subunit was used as a reporter to evaluate mutations of
residues in the extracellular domain that may function as
binding residues or as gating pathway residues.
bL90S as a reporter of functional role
for extracellular residues
Agonist occupancy at both binding sites is required for effi-
cient opening of the channel pore. Scheme 1 shows a simpli-
fied kinetic model for activating the nAChR, leading to an
expression for EC50 (Eq. 2) (18,19), where A is the agonist;
RC and RO denote the closed and open states of the receptor;
k1 and k-1 are forward and reverse rate constants for agonist
binding; KD is the dissociation constant for the agonist; and
Q is the gating equilibrium constant, given by the ratio of
the channel opening rate, b, to the channel closing rate, a. It
is well understood that the actual kinetic model for the nAChR
is likely more complicated, and that different Cys-loop recep-
tors may show kinetic schemes that differ in detail. In
addition, a strong gating mutation could enable spontaneous
openings of the channel when no agonist is bound. This could
compromise the kinetic model discussed here. However, the
bL90S mutation alone does not lead to extensive spontaneous
openings, and the types of mutations emphasized here, if they
impact gating at all, discourage channel opening (decrease
Q), suggesting that spontaneous openings will not produce
a major perturbation to the system. Scheme 1 is typical for
an allosteric receptor, capturing the essence of the situation:
function depends on binding of an allosteric effector as well
as signal transduction (gating). For ligand-gated ion channels,
this means that EC50 depends on KD and Q, where Q is
a measure of receptor efficacy. The graphical representation
of the relationship between EC50 and Q, based on Eq. 2, is
shown in Fig. 2. Simulations of more-complex kinetic
schemes produce qualitatively similar plots. For full agonists
(FAs), that is, those that produce a large Q, the plot is linear
with a negative slope. We will refer to this as the ‘‘high slope’’
region of the plot. For smaller values of Q, such as would be
associated with partial agonism, the plot approaches an
asymptote. We will refer to this as the ‘‘plateau’’ region:
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where KD ¼ k-1/k1 and Q ¼ b/a
EC50 ¼ KDðQ þ 2Þ1=21
: (2)
A defining feature of allosteric proteins is that an allosteric
effector shifts the equilibrium between two states, histori-
cally termed tensed and relaxed. However, binding of the
allosteric effector itself does not define the exact state as
tensed or relaxed, rather it produces a shift in the equilibrium
distribution between these states. Consequently, once the
allosteric signal is saturated, this equilibrium distribution
depends only on the equilibrium constant governing
tensed-relaxed interconversion. In the case of ligand-gated
ion channels, such as the nAChR studied here, different allo-
steric effectors—i.e., different ligands for ligand-gated ion
channels—produce different closed-open equilibria, charac-
terized by Q. Thus, whereas FAs (Q >> 1) cause the
channel to be mostly open when agonist is bound, PAs influ-
ence this allosteric transition to a lesser extent, resulting in
a smaller perturbation of the gating equilibrium. It is the
varying extent to which ligand binding can bias the equilib-
rium that produces the general shape of the relationship
between EC50 (function) and Q, seen in Fig. 2.
Previous studies (17,20–22) have shown that polar muta-
tions at L90 substantially increaseQ, causing a corresponding
drop in EC50. Our goal was to determine whether it was
possible to use a reporter mutation such as bL90S to evaluate
whether the shift in EC50 from mutation at a target residue is
primarily a result of changes in binding (KD) or gating (Q)
(see the Supporting Material, Fig. S1). Consider such a target
FIGURE 2 (Black line) Relationship between EC50 andQ, as given in Eq.
2. (Red line) The same equation but with a larger KD. For both plots, in the
negative slope region changes in Q produce significant changes in EC50, as
shown when the reporter effect is added to the wild-type receptor. However,
when beginning with Q in the plateau region, a much smaller shift in EC50
occurs for equivalent shifts in Q.mutation in the extracellular domain that only increases KD,
i.e., a pure binding mutation. This has the effect of raising the
EC50 versus Q curve, but maintaining its shape (Fig. 2, red
line). Addition of the bL90S mutation then causes a compa-
rable increase in Q, lowering EC50 by the same factor as in
the wild-type. The pairing of an extracellular domain binding
mutation with the reporter transmembrane domain mutation
results in a multiplicative shift in EC50; the two mutations are
independent.
Now, consider the consequences of an extracellular
domain target mutation that affects gating, and not binding.
Deleterious mutations (increase in EC50) will cause a drop in
Q, and if the effect is large enough, the agonist employed
will now be a PA. The EC50 versus Q relationship for this
mutant will now lie in the plateau region of Fig. 2. As a result,
the subsequent increase in Q caused by adding the bL90S
mutation will induce a much smaller drop in EC50. The pair-
ing of these mutations will no longer give a multiplicative
shift in EC50, and therefore the two mutations are function-
ally coupled. Thus, the bL90S gating mutation acts as
a reporter to identify a target mutation that is substantially
loss of function (decreasing Q). It is clear from Fig. 2 that
a gain-of-function gating mutation (lower EC50; increasing
Q) will still be in the high slope region and so will be addi-
tive with the bL90S mutation. This method cannot detect
gain-of-function gating mutations.
For many mutations in the extracellular domain, the bL90S
mutation is multiplicative, producing a consistent 40-fold
shift to lower EC50 (Table 1) (17,23,24). We now report
the first examples of mutations closely associated with the
agonist binding site for which the effect of bL90S is substan-
tially <40-fold, indicating nonmultiplicative behavior
(Fig. 1). Four of these are conventional mutants: aY190F,
gD174NdD180N, gW55YdW57Y, and aD200N. Others
have probed these sites, and they are generally considered
to primarily influence gating (25–31). As such, these studies
validate the ELFCAR method. The fifth, a novel mutant,
replaces aS191 with its a-hydroxy analog, which we abbre-
viate Sah (for serine a-hydroxy), converting the backbone
amide that links aY190 and aS191 to a backbone ester
(32,33).
Mutant cycle analysis suggests long-range
coupling
The typical way to analyze a system in which two mutations
are evaluated, individually and in tandem, is by mutant cycle
analysis (Fig. 3). Briefly, if a mutation at one site has no
structural or energetic impact at a second site, then the effect
of simultaneous mutations at both sites will simply be multi-
plicative (Fig. 3). In the parlance of mutant cycle analysis,
the coupling parameter, U, will be unity. In contrast, if two
residues interact, the simultaneous mutation at both sites
will lead to an effect that is either greater or less than the
product of their individual effects, producing an U-valueBiophysical Journal 96(8) 3168–3178
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0S reporter
mutation for coupled and noncoupled residues
Target mutation WT EC50 EC50 with reporter mutation Ratio U
bL90S
Wild-type 46 1.2 38 1.00
gD174NdD180N 590 160 3.7 11
aY190F 1200 520 2.3 17
gW55YdW57Y 180 24 7.5 5.1
aD200N 130 29 4.5 8.6
aS191Sah 300 50 6.0 6.4
aE45W 120 3 40 0.96
aY93Yah 39 1 39 0.98
aN94Nah 87 2.2 40 0.97
aD97E 3.3 0.09 37 1.0
aM144L 15 0.37 41 0.95
aM144Lah 50.4 1.3 39 0.99
aK145Q 170 8.1 21 1.8
aL146Lah 26 0.5* 52 0.74
aT148Tah 33 1.3 25 1.5
aW149Wah 36 0.72 50 0.77
aW149 5-F-Trp 200 4.7 43 0.90
aW149 5-Br-Trp 88 2 44 0.87
aL199Lah 11 0.18 61 0.63
aT202Tah 24 0.48 50 0.77
aY203Yah 39 0.62 63 0.61
aF205Yah 67 1.4 48 0.80
aF205Y 90 1.5 60 0.64
aV206Vah 170 3.1 55 0.70
gL36dL39Lah 28 0.63 44 0.86
gI56dI58Iah 33 0.83 40 0.96
gA121dA124Aah 25 0.66 38 1.0
gE168QdE175Q 42 1.2 35 1.1
gL90S
Wild-type 46 4.5 10 1.0
gD174NdD180N 590 244 2 4.2
aY190F 1200 650 2 5.5
gW55YdW57Y 180 74 2 4.2
dL90S
Wild-type 46 1 46 1.0
gD174NdD180N 590 140 4 11
aY190F 1200 370 3 14
gW55YdW57Y 180 16 11 4.1
aL90S
Wild-type 46 0.35 131 1.0
gD174NdD180N 590 65 9 14
aY190F 1200 223 5 24
gW55YdW57Y 180 7.5 24 5.5
aV130S
Wild-type 46 0.1 460 1.0
gD174NdD180N 590 8.9 66 7
aY190F 1200 32 38 12
gW55YdW57Y 180 1.5 120 3.8
aL160S
Wild-type 46 0.47 98 1.0
gD174NdD180N 590 59 10 10
aY190F 1200 190 6 15
gW55YdW57Y 180 8.5 21 4.6
Values for the three coupled residues are also given for reporter mutations in
all other subunits (g, d, and a) and positions (90, 130, and 160). The ratio of
EC50s: target/target with reporter, and resultant calculated U-values are also
reported. The standard error for all EC50 values was <10%, except for *,
which had standard error of 20%. Data at sites a148(51), a149(24), and
aS191(47) have been reported previously.Biophysical Journal 96(8) 3168–3178that significantly deviates from unity. This approach has
been broadly applied to a wide range of systems, including
Cys-loop receptors, where several investigators have used
mutant cycle analysis of EC50 values to determine functional
coupling between neighboring residues of the extracellular
domain (34–36).
As could be anticipated from the EC50 values in Table 1, the
majority of mutations made in the extracellular domain of the
nAChR produce an U for coupling to bL90S of ~1, indicating
the functional independence of these residues. However, the
five mutations noted above—aY190F, gD174NdD180N,
gW55YdW57Y, aD200N, and aS191Sah—produced larger
U-values. We consider a value ofU> 2 to signify a meaning-
ful coupling (Fig. 4). Phenomenologically, this establishes
a long-range coupling between these extracellular domain
sites and the bL90 site, as one would expect for an allosteric
receptor. Typically, an U that deviates significantly from
a value of 1 is interpreted to indicate a direct interaction
between the residues, such as a hydrogen bond or a salt bridge.
In this work, though, such a direct interaction is clearly impos-
sible. We feel the interpretation of Fig. 2 is much more palat-
able. Significant coupling is seen because both the bL90S
mutation and the particular extracellular domain mutation
disrupt the gating pathway.
Single-channel recording supports whole-cell
mutant cycle analysis conclusions
The most convincing way to evaluate the impact of a partic-
ularly interesting mutation is by single-channel analysis. To
test our interpretation of the mutant cycle analyses using
EC50 values, we chose three extracellular domain mutants
that ELFCAR identified as gating pathway residues
(aY190F, gD174NdD180N, and gW55YdW57Y) for
single-channel studies. From these recordings, the open
probability in the patch, NPopen was obtained. N is the
number of channels in the patch, which often cannot be
precisely determined. Popen is derived from Scheme 1 and
FIGURE 3 Scheme for double mutant cycle analysis where A and B repre-
sent amino acid positions and A0 and B0 represent mutations at these sites.
The coupling parameter, U, is calculated from the given equation.
Long-Range Coupling in Receptors 3173FIGURE 4 Values of U (coupling to bL90S) for muta-
tions considered here. The standard 40-fold shift expected
for a bL90S mutation produces an U-value of one (hori-
zontal line). 5-F-Trp is 5-fluorotryptophan and 5-Br-Trp
is 5-bromotryptophan. For a-hydroxy acids (Yah, Nah,
Lah, Tah, Wah, Vah, Iah, and Aah), a three-letter abbrevi-
ation is used: the one-letter code for the parent amino acid
is followed by ah; thus Yah is the a-hydroxy acid of
tyrosine.depends only on Q at equivalent points on the dose-response
relation. The NPopen measurements reported were obtained
using the macroscopic EC50 concentration of ACh, and thus
represent 0.5(NPopen,max). Each of the three target mutations
produces a large decrease in NPopen (Fig. 5; Table 2)
compared to the wild-type value of ~0.5 (data not shown);
they are substantially deleterious gating pathway mutations.
Also consistent with the model, adding the bL90S mutation
substantially increases NPopen. The single-channel analysis
thus supports the interpretation of the macroscopic EC50 data.
Other reporter mutations support gating pathway
assignments
An implication of this experimental strategy is that other resi-
dues in the transmembrane domain that substantially
increase Q could act as reporters for extracellular domain
residues; we are not limited to the b-subunit or the well-char-
acterized L90 position. To test this notion, L90S mutations
were made in the a-, g-, and d-subunits, and two other Ser
mutations were made in the M2 helix of the a-subunit at
positions V130 and L160 (Fig. 1). All of these mutations
lower EC50 significantly, and all positions are confidently
ascribed to be gating residues. As shown in Fig. 6, the extra-
cellular domain mutations that give significant U-values with
bL90S also show significant U-values with L90S mutations
present in the other subunits. Recalling that there are two
a-subunits, we find a general coupling parameter sequence
of b z d > a > g. Thus, subtle asymmetries between
subunits exist regarding the L90 residues’ contribution to
gating, which are also reflected in the EC50 values of the
various L90S mutants (Table 1). If one considers positions
other than 90, all the mutated gating pathway residues again
produce meaningful U-values, and the magnitude of their
effect is consistently a90 > a160 > a130 (Fig. 6).
The reporter mutation bL90S systematically
increases Imax for gating pathway residues
This interpretation of the mutant cycle analysis data predicts
other behaviors for extracellular gating pathway residues.For example, to produce a significant mutant cycle analysis
coupling to L90 (U >2), the mutation in the extracellular
domain must convert ACh to a PA, such that the target muta-
tion is now in the plateau region of Fig. 2. Due to this
decrease in Q, the maximal current observed in response
to saturating concentrations of ACh (Imax) should diminish.
In general, interpreting differences in Imax can be chal-
lenging due to variations in whole-cell current among
oocytes, which can stem from various sources that may
or may not relate to the actual mutation in question.
However, use of a reporter mutation can assist in the inter-
pretation of Imax differences. For mutations that render ACh
a PA, increasing efficacy through a reporter mutation
produces a significant systematic increase in Imax (Fig. S2).
We find that these increases are larger and more consistent
than the typical variability in Imax in conventional mutagen-
esis studies. Thus, if a receptor with a target mutation
shows a large increase in mean Imax on introduction of
a reporter mutation, the mutation likely affects gating.
This is shown in Fig. 7 for mutations with large U-values,
along with several examples with U near one. Recovery of
Imax by introduction of the reporter mutation confirms the
gating pathway residue assignments made by mutant cycle
analysis. Moreover, the single-channel observations support
this interpretation, in that the increase in NPopen is the
microscopic correlate of the macroscopic observation of
recovery of Imax (Table 2; the quantitative differences
between U, Imax, and NPopen are considered in the Support-
ing Material).
Experiments with the PA SuCh support gating
pathway assignments
Given the argument that a substantially deleterious mutation
of a gating pathway residue converts the FA ACh to a PA,
which manifests as a diminished Imax, it is interesting to
consider the behavior of an inherent PA, such as SuCh
(37). The relative efficacy, 3, of a PA can be defined as the
ratio of the maximal current elicited by a PA to the maximal
current elicited by a FA (Eq. 3). At saturating doses ofBiophysical Journal 96(8) 3168–3178
3174 Gleitsman et al.agonist, all the receptors are presumed to be in a diliganded
state (A2R), meaning that differences in Imax for the two
agonists are due to differences in the probability that a single
channel is open when the binding equilibrium is saturated,
Popen,max. For wild-type muscle nAChR, SuCh is a PA
with ~4% efficacy relative to ACh.
FIGURE 5 Single-channel currents for select mutants. In each case, ACh
is applied at the macroscopic EC50 value (Table 1), and the left panel has no
reporter mutation, whereas the right panel is for receptors with the bL90S
reporter mutation. For each of the six receptors, the lower trace (5 s) depicts
an expansion of the section of the upper trace indicated with a line. Records
were obtained in the cell-attached configuration with a pipette potential of
þ100 mV and are shown at 5 kHz bandwidth. Channel openings are shown
as downward deflections. (A) aY190F; (B) gD174NdD180N; and (C)
gW55YdW57Y.Biophysical Journal 96(8) 3168–31783 ¼ Imax;PA
Imax;FA
¼ Popen;max;PA
Popen;max;FA
;Popen;max ¼ b
a þ b ¼
Q
Q þ 1
(3)
In the presence of an L90S mutation alone, SuCh becomes
a FA (see Fig. S3). Three of the five gating pathway residues
were characterized using the PA SuCh. Unlike what is
observed for binding mutations, when aY190F,
gD174NdD180N, and gW55YdW57Y contained a L/S
mutation at either the 90 (a or b), 130 (a), or 160 (a) site,
the recovery of SuCh toward full agonism is blocked. As
before, the magnitude of the effect follows the trend a90 >
a160 > a130 (data not shown). This is interpreted as further
evidence that mutation of these extracellular domain residues
drastically impairs normal gating function. Note that the effi-
cacies of SuCh for the gating pathway mutants without the
L90S reporter mutation are not dramatically different from
that of wild-type (0.04  0.02 for wild-type, 0.04  0.01
for aY190F, 0.02  0.01 for gD174NdD180N, and
0.01  0.0009 for gW55YdW57Y). This again highlights
how the use of a reporter mutation can uncover important
aspects of receptor function that might otherwise be missed.
DISCUSSION
In this work, we propose that appropriately designed double
mutant studies can provide valuable insights into the mech-
anism of action of an allosteric receptor. We begin with
a mutation at a site whose function is unambiguous. Here,
this reporter residue can be one of several sites in the trans-
membrane region of a ligand-gated ion channel, far removed
TABLE 2 Coupling parameter, U, and Imax ratio from whole-
cell data. NPopen values (mean SE) at respective macroscopic
EC50 values (Table 1)
Mutant U Imax ratio NPopen NPopen bL9
0S
aY190F 17 11 0.0026  0.0006 0.18  0.04
gD174NdD180N 11 13 0.0007  0.0005 0.08  0.06
gW55YdW57Y 5 12 0.018  0.005 0.26  0.06
FIGURE 6 Values of U for various reporter mutations. For each of the
three extracellular domain mutations, results for six different reporter muta-
tions are shown. Reporter mutations are identified by their location, in each
case, the mutation is of a hydrophobic residue to serine.
Long-Range Coupling in Receptors 3175from the agonist binding site. It is assumed that mutations at
this site primarily, if not exclusively, perturb the gating of the
receptor, and this view is supported by detailed studies of the
reporter mutations. A second site, the target site, can then be
probed by combining mutations there with a reporter muta-
tion. Here we consider a number of target sites that are far
removed from the reporter residue. Analysis of the results
can proceed along several lines. The classical tool is a mutant
cycle analysis. Indeed we find that, whereas most pairings of
remote residues produce independent behavior (U ~ 1), for
select target residues a mutant cycle analysis produces strong
coupling parameters. Typically, such coupling is interpreted
to indicate a direct interaction between the residues.
However, in all cases here, the residues are much too far
apart to accommodate a direct structural interaction. As
such, we have an allosteric coupling between remote resi-
dues, which manifests in a mutant cycle analysis just as if
the two were structurally coupled. Of course, such action
at a distance is the definitive feature of an allosteric system,
but there are few cases where such pairwise interactions have
been seen. Because the reporter mutation influences gating,
coupling requires that the target residue also impact gating,
allowing an apparent long-range interaction to be revealed
in the mutant cycle analysis. We have labeled such residues
as being on the ‘‘gating pathway’’, with the understanding
that any mutation that preferentially stabilizes one state of
the receptor could produce a positive result in ELFCAR,
regardless of its location in the receptor. The particular resi-
dues studied here, however, do lie in regions of the receptor
that have been considered to be part of the primary structural
transduction from binding site to channel gate.
A less-phenomenological analysis can be made with refer-
ence to Fig. 2. The key here is that if the mutation at the
FIGURE 7 Variation in Imax in response to introduction of a bL9
0S
reporter mutation.target site perturbs gating by decreasing Q, moving the
system to the left along the EC50 versus Q curve, and, if
the effect is large enough, the system will now be in the
plateau region. Then, when the reporter mutation is added,
its effect on EC50 will be diminished relative to what is
seen in the receptor that is wild-type at the target site. To
be informative, the mutation at the target site must be loss
of function (diminishedQ) and must have a substantial effect
on gating. If Q is diminished only slightly by the target
mutation, or if Q is increased (gain of function) the system
will remain in the region of high slope, and the reporter
mutation will have its normal effect. Also, when we do see
significant coupling, that does not rule out the possibility
that KD has changed in addition to Q; ELFCAR can only
establish that a significant decrease in Q has occurred. At
the same time, when a target mutation produces a large shift
in EC50 but a conventional 40-fold additional shift on adding
the bL90S reporter mutation, it is tempting to conclude that
the target mutation exclusively impacted KD. However,
changes in Q that are significant but not large enough to
move the system into the plateau region of Fig. 2 could be
involved in addition to or instead of a KD change. For
example, the K145Q mutation has been reported to impact
gating (28), but without moving Q into the plateau region.
In this work, K145Q shows a marginal functional coupling
with L90S, with an U-value near the cutoff for significance
(1.8  0.2). As such, ELFCAR is best suited to identifying
mutations that strongly perturb gating (U > 2); negative
results should be interpreted cautiously. Note that in recep-
tors for which the wild-type Q is smaller than in the
muscle-type nAChR, ELFCAR would be expected to be
more sensitive to small changes in Q.
Several additional observations support our analysis of the
results seen here. First, in a typical mutant cycle analysis,
U-values <1 can be observed and are functionally significant.
However, in this context, the model of Fig. 2 allows only for
U > 1, which is consistent with our data. Importantly, three
mutations shown here to impact gating by the ELFCAR
approach have been confirmed to be gating mutations by
single-channel analyses. The single-channel values we report
areNPopen. The true probability that a single channel is open at
these concentrations,Popen, is increased by a factor ofN, where
N is the number of channels in the patch. Because the measured
probability that the channel is open is low (%2%) for the
gating pathway mutations without the reporter mutation, the
number of channels in the patch cannot be determined.
However, if there are actually multiple channels in these
patches, our NPopen values would be overestimates of Popen.
The measured NPopen values are substantially diminished
upon addition of each of the three target residues we tested
(aY190F, gD174NdD180N, and gW55YdW57Y), such that
the modest perturbation of EC50 associated with the target
mutations can be primarily ascribed to dramatic changes in
the gating pathway. Other single-channel studies of residues
considered here are also consistent with our findings.Biophysical Journal 96(8) 3168–3178
3176 Gleitsman et al.Other observations support our general model. If a target
mutation substantially reduces Q, then ACh should become
a PA at the receptor. This should lead to reduced maximal
currents from whole-cell recordings, and just such an effect
is seen. Also, an inherent PA should be sensitive to the
consequences of the target mutation, and we find that is
the case for SuCh.
It is interesting to consider the residues that have been
probed here; Fig. 1 highlights them all. The considerable
distance between the reporter residues and the target residues
is clear from this image. Concerning the target residues,
those with no strong coupling (purple) are dispersed
throughout the extracellular domain, and, although only
five have been identified so far, the same is true of the gating
pathway residues (orange). There is no simple pattern that
distinguishes the two classes.
The agonist binding site of the nAChR is an ‘‘aromatic
box’’, shaped by five conserved aromatic residues: aY93
(A), aW149 (B), aY190 (C1), aY198 (C2), and gW55/
dW57 (D) (6,38). The letter designations signify the ‘‘loop’’
of the extracellular domain that contains the particular residue
(39). Because all the natural agonists of Cys-loop receptors
have a cationic group, the presence of the aromatic box sug-
gested that a cation-p interaction contributes to agonist
binding (40,41). Indeed, aW149 (B) and the aligning residues
have been shown to contribute to agonist binding through
a cation-p interaction in both the nAChR and the 5-HT3 recep-
tors (24,42). We find U ~ 1 consistent with a binding role for
this residue. Note that subtle mutations have been employed at
this site, taking advantage of the power of unnatural amino-
acid mutagenesis. We cannot rule out the possibility that
more disruptive mutations at this and other sites would impact
receptor gating. Indeed, the aW149F mutation has been
probed, and it impacts binding and gating (43). Most of the
mutations in Table 1 are, by conventional standards, subtle,
and we would argue that some caution must by employed in
interpreting the consequences of more severe mutations.
The residue analogous to aY198 (C2) has been shown to
bind serotonin through a cation-p interaction in the MOD-1
receptor (44). Previous studies in the nAChR show that
mutations at this site exhibit normal coupling to L90S muta-
tions (45). Single-channel studies of the aY198F mutant
indicate only modest changes in gating (26) that would be
outside the limits of detection for ELFCAR.
The residue aY93 (A) has been extensively probed. In the
GABAA receptor the analogous residue makes a cation-p
binding interaction to the native agonist (46). In the nAChR,
side-chain mutations at this site strongly impact channel
gating. However, the mutation studied here, aY93Yah, is
a backbone mutation. Our finding of U ~ 1 indicates no
strong perturbation of gating by a backbone mutation in
this region. This conclusion is supported by the similar result
at the adjacent residue (aN94Nah).
The remaining two box residues, aY190 (C1) and gW55/
dW57 (D), have never been shown to make a cation-p inter-Biophysical Journal 96(8) 3168–3178action with an agonist. Both are assigned as gating pathway
residues according to the ELFCAR method. aY190 has been
extensively studied. That aY190F strongly impacts gating is
unambiguously established by the single-channel records of
Fig. 5 A. Other workers have also found strong perturbations
to gating for mutations at this site (27,28). Some studies have
also found a contribution to binding, but, as discussed above,
this work does not address this issue. The important point is
that the finding of a large U-value in ELFCAR is supported
by single-channel studies. In addition, a backbone mutation
at the adjacent residue, aS191Sah, also produces a large
U-value in ELFCAR. We have recently shown that this
residue makes a strong hydrogen bond to a side chain from
the complementary subunit (g/d) and that the hydrogen
bond contributes significantly to gating (47). Most gating
models for the nAChR invoke considerable movement of
loop C (6,48,49), and the finding of large U-values for these
two loop-C residues is consistent with these models.
The final binding box residue, gW55/dW57 (D), shows
a large U-value for the Tyr mutant. Our single-channel
studies (Fig. 5 C) establish an impact on gating for this muta-
tion. Previous single-channel studies of the Phe mutant show
a small effect on binding (3.4-fold) and a large effect on
gating (50-fold) (50), consistent with these results. There is
reason to anticipate that loop D may also undergo significant
rearrangements during gating. In Unwin’s image of the
Torpedo nAChR (7), with no agonist bound, TrpD is flipped
out away from the box that is so well formed in AChBP (with
or without agonist bound). This again suggests that move-
ment of TrpD occurs on ligand binding, consistent with it
being a gating pathway residue.
The fifth gating pathway residue we identified, aD200, is
not part of the aromatic binding box but appears to lie outside
the box. However, it is part of a triad of residues that includes
aY190 and aK145 and that has been suggested to undergo
significant rearrangement on gating (28). Previous single-
channel studies have shown that mutation at this site perturbs
gating (25,28). As such, the large U seen here with ELFCAR
is consistent with other studies.
CONCLUSIONS
In this work, we have developed an efficient strategy for
identifying mutations that impact receptor function by signif-
icantly impeding the gating pathway. The method involves
combining mutations of extracellular domain residues
proposed to be functionally important with a known gating
pathway (reporter) mutation. For interesting sites, ELFCAR
can provide guidance for more focused, advanced studies,
such as detailed unnatural amino acid mutagenesis of puta-
tive binding residues or single-channel analysis, where
possible, for gating residues.
The kinetic model of Scheme 1 refers to the nAChR, but it
contains the essential features of any allosteric system. There
is a binding interaction with an allosteric effector and an
Long-Range Coupling in Receptors 3177intrinsic conformational change associated with the signaling
event. The former is a bimolecular association, and so is satu-
rable at high ligand concentration. However, the conforma-
tional change is unimolecular, and so it is an intrinsic property
of the system. It is the combination of these two processes that
produces the curvature of Fig. 2 and thus allows for the
specific application of mutant cycle analysis presented here.
As such, we anticipate that the same approach could be
applied to other allosteric systems, allowing a facile means
to identify the roles of particular residues in a complex protein
system. Thus, although this study has focused on a single Cys-
loop receptor, we believe the approach is broadly applicable
to other Cys-loop receptors and to allosteric receptors in
general. Certainly, comparable reporter residues can be found
in the other Cys-loop receptors; the L90 residue is highly
conserved and it seems likely to play an important gating
role throughout the family. We emphasize that, although all
members of the Cys-loop family are genetic orthologs, func-
tional paralogs, and structural homologs, there is growing
evidence that the detailed mechanisms of action will vary
from system to system (41). Thus, this approach, based on
the readily obtained EC50 measure, offers a robust and effi-
cient way to search for such variations in gating mechanism.
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